

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/981,155	10/16/2001	Rodney Scott Armentrout	71418	5616
7:	590 11/29/2002			
Cheryl J. Tubach			EXAMINER	
Eastman Chemi P.O. Box 511	ical Company		MULLIS, JEFFREY C	
Kingsport, TN	37662-5075		ART UNIT PAPER NUMBER	
			1711	ر
			DATE MAILED: 11/29/2002	5

Please find below and/or attached an Office communication concerning this application or proceeding.

•	Application No.	Applicant(s)	
	''		T A1
· Office Action Summary	09/981,155	ARMENTROUT E	T AL.
	Examiner	Art Unit	1
The MAILING DATE of this communication app	Jeffrey C. Mullis	with the correspondence ad	ldress
Period for Reply		inii ine con coponaciice aa	u/ 000 -
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a repl - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute - Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b). Status	136(a). In no event, however, may by within the statutory minimum of t will apply and will expire SIX (6) Me a, cause the application to become	a reply be timely filed nirty (30) days will be considered timel DNTHS from the mailing date of this considered timel ABANDONED (35 U.S.C. § 133).	
_			
1) Responsive to communication(s) filed on			
,	nis action is non-final.		
3) Since this application is in condition for allow closed in accordance with the practice under			ie ments is
Disposition of Claims			
4)⊠ Claim(s) <u>1-42</u> is/are pending in the application			
4a) Of the above claim(s) is/are withdra	wn from consideration.		
5) Claim(s) is/are allowed.			
6) ☐ Claim(s) is/are rejected.			
7) Claim(s) is/are objected to.			
8) Claim(s) <u>1-42</u> are subject to restriction and/or	election requirement.		
Application Papers			
9) The specification is objected to by the Examine			
10) ☐ The drawing(s) filed on is/are: a) ☐ acce			
Applicant may not request that any objection to the			
11) The proposed drawing correction filed on		disapproved by the Examin	er.
If approved, corrected drawings are required in re			
	Kailiillet.		
Priority under 35 U.S.C. §§ 119 and 120	n naiority under 25 H C C	2	
13) ☐ Acknowledgment is made of a claim for foreiga) ☐ All b) ☐ Some * c) ☐ None of:	ii priority under 35 O.S.C	. 9 119(a)-(u) or (i).	
1. Certified copies of the priority document	ts have been received		
2. Certified copies of the priority document		Application No.	
Copies of the certified copies of the prior		_	Stage
application from the International Bu * See the attached detailed Office action for a list	ureau (PCT Rule 17.2(a)).	Glage
14) Acknowledgment is made of a claim for domest	ic priority under 35 U.S.	C. § 119(e) (to a provisiona	l application).
 a) ☐ The translation of the foreign language prediction 15)☐ Acknowledgment is made of a claim for domest 	· · ·		
Attachment(s)			
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) _	5) Notice	w Summary (PTO-413) Paper No of Informal Patent Application (PT	
S. Patent and Trademark Office			

Serial No. 09/981,155
 Art Unit 1711

The following is a requirement for <u>election of species and</u>

restriction between two groups of inventions. In order to be

fully responsive, applicants must respond to both the election of species and the restriction between groups of inventions.

Restriction to one of the following inventions is required under 35 U.S.C. § 121:

- I. Claims 1-22, drawn to a product, classified in Class 525, subclass 54.3.
- II. Claims 23-42, drawn to a process, classified in Class 528, subclass 486.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the product as claimed can be made by another materially different process such as a process in which a protected end capping monomer containing a hydroxyl group such as a polyalkylene glycol having a protected acid end group is reacted with a hard segment and then the protecting group removed.

Serial No. 09/981,155

Art Unit 1711

This application contains claims directed to the following patentably distinct species of the claimed invention: Applicants are required to elect a single alkylene glycol (polyether) from one of those in claim 6; applicants also are required to elect a single hard segment polymer by electing either polyurethanes or polyamides or polycarbonates or a hard segment from which polyetheresteramides are formed; applicants are also required to elect a single acid end capping free agent by selecting one of those in claim 17; applicants are also required to elect a single thermoplastic base material from one of those in claim 21.

Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim [2] generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37

Serial No. 09/981,155
Art Unit 1711

CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. § 103(a) of the other invention.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must

Serial No. 09/981,155

Art Unit 1711

be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Due to the complexity of this election/restriction, no telephone election/restriction was attempted.

Any inquiry concerning this communication should be directed to Jeffrey Mullis at telephone number (703) 308-2820.

J. Mullis:cdc

November 25, 2002

